Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of docetaxel and cisplatin in advanced adrenocortical carcinoma
2005-001341-42Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cisplatin in adrenal cancer (ACC), sponsored by Rigshospitalet. Primary endpoints: Objective response rate and Treatment-related toxicity. Started Feb 2006; status: completed.
02
Drugs
docetaxelcisplatin
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2005-001341-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001341-42.